logo 2 4037

Pill imprint logo 2 4037 has been identified as Estazolam 2 mg.

Estazolam is used in the treatment of insomnia and belongs to the drug class benzodiazepines. Not for use in pregnancy.

Estazolam 2 mg has a low potential for abuse. The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs in schedule 3.
See also related documents.

Estazolam Images

Estazolam

Imprint:: logo 2
4037
Strength:: 2 mg
Color:: Pink
Shape:: Four-sided
Availability:: Prescription only
Drug Class:: Benzodiazepines
Pregnancy Category:: X - Not for use in pregnancy
CSA Schedule:: 4 - Some potential for abuse
Manufacturer:: Teva Pharmaceuticals USA

View Drug Details Print Page

More Estazolam resources

Estazolam (Wolters Kluwer)
estazolam (Cerner Multum)
estazolam (Micromedex) - Includes Dosage Information
Estazolam (AHFS DI)
Estazolam (FDA)
Estazolam (Wolters Kluwer)

Estazolam is associated with the treatment of:

Insomnia

Search Again

Search by Imprint, Shape or Color

Note: All fields optional. Use the pill finder to identify medications by visual appearance or name.

Imprint:
Color:
Shape:

Sign In or Register

Forgot password?

Related Estazolam Information

Availability Prescription only

CSA Schedule Some potential for abuse

Pregnancy Category Not for use in pregnancy

Approval History Drug history at FDA

Reviews

Average User Rating

6 User Reviews

9.7

Rate it!

Related Pages

Drug Class

Benzodiazepines

Recently Approved

Mitosol
Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.
Sklice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ...
Jentadueto
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ...
Kalydeco
Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated ...
Erivedge
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ...

More...

FDA Consumer Updates

More FDA Updates...

Related News and Articles

FDA Approves Middle-of-the-Night Insomnia Pill 28 November 2011
Federal health regulators say they have approved the first insomnia pill designed for people who wake up in the middle of the night and have trouble getting...
FDA Approves Intermezzo for Middle-of-the-Night Waking Followed by Difficulty Returning to Sleep 23 November 2011
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by...
Transcept Pharmaceuticals Announces Intermezzo PDUFA Action Date of November 27, 2011 7 October 2011
Transcept Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has classified the recent...
Transcept Pharmaceuticals Resubmits Intermezzo NDA to FDA 29 September 2011
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products...
Mixed Results Seen With 'Off-Label' Use of Antipsychotics 27 September 2011
Even though off-label use of atypical antipsychotic drugs is common, a new review finds that such use is only effective in a few conditions and can be harmful...

Get Updates by Email

Email me about estazolam systemic:

Did you find this page helpful? Yes No

Support

About Drugs.com

Your Privacy

Follow us on: Google+ Facebook Twitter

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.

Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.

We comply with the HONcode standard for trustworthy health information.
Verify here

Terms of Use · Privacy Policy